

SEPTEMBER 24, 2016 – SATURDAY MEET THE EXPERT SESSIONS

7-8 am	Catastrophic Antiphospholipid Syndrome Ricard Cervera (Spain) Room1: TBD	Catastrophic Antiphospholipid Syndrome (Turkish) Doruk Erkan (USA) Room2: TBD	Pediatric Antiphospholipid Syndrome Tadej Avcin (Slovenia) Room3: TBD	Pediatric Antiphospholipid Syndrome (Turkish) Arzu Soybilgic (USA) Room4: TBD
---------------	---	--	--	--

SEPTEMBER 24, 2016 – SATURDAY MORNING SESSIONS

MAIN SESSION 9 Prevention and Treatment of Thrombotic Antiphospholipid Syndrome:		DEEP DIVE SESSION 9 Natural Proteins Involved in Antiphospholipid Syndrome	
Moderators	Mark Crowther (Canada), Doruk Erkan (USA), Vedat Hamuryudan (Turkey)	Moderators	Philip G de Groot (Netherlands), Steve Krilis (Australia)
Room	Hall A	Room	Hall B
8.00 am	General Review - Primary Thrombosis Prevention Doruk Erkan (USA)	8.00 am	Introduction & General Review Philip G de Groot (Netherlands)
8.20 am	General Review – Secondary Thrombosis Prevention Mark Crowther (Canada)	8.20 am	The Structure and Post-Translational Modification of β_2-Glycoprotein-I Steve Krilis (Australia)
8.40 am	Importance of Cardiovascular Disease Prevention in APS Ian Bruce (UK)	8.40 am	Reimagining APS Through the Door of Imaging: The Role of Macro-immune Complexes in APS Jacob Rand (USA)
9.00 am	Can we Stop Anticoagulation in APS Patients with Previous Thrombosis? David Garcia (USA)	9.00 am	Small angled X-ray Scattering of β_2-Glycoprotein-I Bas de Laat (Netherlands) (Online Presentation)
9.20 am	Hydroxychloroquine in APS – Where do we stand? Maria G. Tektonidou (Greece)	9.20 am	Platelet-derived Chemokine and Endothelial Cell Interaction in APS Panayiotis Vlachoyiannopoulos (Greece)
9.40 am	Group Conclusions	9.40 am	Group Conclusions
9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions	9.45 am 10.30 am	Coffee Break, Exhibition, and Poster Discussions

MAIN SESSION 10 Prevention & Treatment of Obstetric Antiphospholipid Syndrome		DEEP DIVE SESSION 10 New Generation Antiphospholipid Antibody Tests	
Moderators	Ware Branch (USA), Guilherme De Jesus (Brazil)	Moderators	Maria Laura Bertolaccini (UK), Bahar Artim Esen (Turkey)
Room	Hall A	Room	Hall B
10.30 am	Assessment of Fetal Death - The Role of aPL and Other Confounding Factors Robert Silver (USA)	10.30 am	Anti-β_2-Glycoprotein-I/HLA class II Complex Antibodies in APS Hisashi Arase (Japan)
10.55 am	What is the Impact of Treatment in Obstetric APS? Ware Branch (USA)	10.50 am	Anti-Domain IV/V Antibodies Pier Luigi Meroni (Italy)
11.20 am	ARA (I&E) – OP10 - Antiphospholipid Antibodies in Women with Preterm Delivery for Preeclampsia or Placental Insufficiency (PREPI) Karen J. Gibbins (USA), Anne E. Tebo, Samantha Nielsen, D. Ware Branch	11.10 am	Annexin A5 Resistance Assay and Alternative Functional Assays Jacob Rand (USA)
11.35 am	ARA (I&E) – OP11 - Recurrent Pregnancy Loss in Women with and without aPL Karen J. Gibbins (USA), Lindsey A. Sjaarda, D. Ware Branch, Sunni L. Mumford, Neil J. Perkins, Enrique F. Schisterman, Robert M. Silver	11.30 am	Thrombin Generation Tests for Functional Effects of aPL Denis Wahl (France)
11.50 pm	OP26 - Beneficial Effects of Pravastatin in the Management of Obstetric APS Refractory to Antithrombotic Therapy Eleftheria Lefkou, Apostolos Mamopoulos, Themistoklis Dagklis, Christos Vosnakis, David Rousso, <u>Guillermina Girardi (UK)</u>	11.45 am	Anti-Factor X Antibodies Bahar Artim Esen (Turkey)
12.05 pm	Group Conclusions	12.00 pm	APhL Enzyme-linked Immunosorbent Assay (ELISA) Rohan Willis (USA)
12.15 pm 1.30 pm	Lunch Break & Satellite Symposium	12.15 pm 1.30 pm	Lunch Break & Satellite Symposium

SEPTEMBER 24, 2016 – SATURDAY PATIENT WORKSHOP

Antiphospholipid Syndrome and Systemic Lupus Erythematosus	
Moderators	English Joann Vega (USA) Room3: Turkish Ayten Yazici (Turkey) Room4:
Speakers	Bahar Artim Esen (Turkey), Doruk Erkan (USA), Murat Inanc (Turkey), Arzu Soybilgic (USA)
10.30 am 12.15 pm	Introduction Basic Immunology for Antiphospholipid Syndrome & Lupus Patients Antiphospholipid Syndrome & Lupus: <ul style="list-style-type: none">• Clinical Manifestations• Kidney Disease• Management• Damage and Prevention Strategies• Pregnancy• Importance of Drug Adherence Pediatric Antiphospholipid Syndrome & Lupus Questions & Answers
Sponsored by an Educational Grant from Creaky Joints	

SEPTEMBER 24, 2016 – SATURDAY NOON SATELLITE SYMPOSIUM

Antiphospholipid Syndrome and Systemic Lupus Erythematosus	
Moderators	Doruk Erkan (USA), Murat Inanc (Turkey)
Room	Hall A
12.15 pm	Introduction Doruk Erkan (USA), Murat Inanc (Turkey)
12.30 pm	Are There Lessons Learned from Lupus Clinical Trials that are Applicable to Antiphospholipid Syndrome? Richard Furie (USA)
1.15 pm	Questions & Answers
Sponsored by an Unrestricted Educational Grant from GSK	

SEPTEMBER 24, 2016 – SATURDAY AFTERNOON SESSIONS

MAIN SESSION 11 Management of Non-Criteria Manifestations in Antiphospholipid Syndrome		DEEP DIVE SESSION 11 Antiphospholipid Syndrome Classification Criteria Task Force Report	
Moderators	Danieli Andrade (Brazil), Richard Furie (USA), Michelle Ugolini (Brazil)	Moderators	Doruk Erkan (USA), Sedat Kiraz (Turkey), Stephane Zuily (France)
Room	Hall A	Room	Hall B
1.30 pm Case Presenter: Expert Opinion:	Antiphospholipid Antibody Nephropathy Maria G. Tektonidou (Greece) Maria G. Tektonidou (Greece)	1.30 pm	Sapporo APS Classification Criteria: Historical Perspective Takao Koike (Japan)
1.55 pm Case Presenter: Expert Opinion:	Severe Thrombocytopenia Michelle Ugolini (Brazil) Reyhan Diz Kucukkaya (Turkey)	1.50 pm	Strengths and Limitations of Updated Sapporo APS Classification Criteria Ronald Derksen (Netherlands)
2.20 pm Presenter: Expert Opinion:	Cardiac Valve Disease Ozan Unlu (Pre-recorded, USA) Mary Carmen Amigo (Mexico)	2.10 pm	14th International Congress on aPL Task Force Report on “Non-criteria” Clinical Manifestations Roger Levy (Brazil)
2.45 pm Presenter: Expert Opinion:	Skin Ulcers Michelle Ugolini (Brazil) Kurosh Parsi (Australia)	2.30 pm	15th International Congress on aPL New APS Classification Criteria Initiative – Where Do We Stand? Doruk Erkan (USA)
3.10 pm	Group Conclusions	2.50 pm	Meta-analyses in APS: What Do We Know and How Do They Help Us Develop New Classification Criteria? Denis Wahl (France)
		3.10 pm	Group Conclusions
3.15 3.45	Coffee Break, Exhibition, and Poster Discussions	3.15 3.45	Coffee Break, Exhibition, and Poster Discussions

MAIN SESSION 12 Neuropsychiatric Antiphospholipid Syndrome		DEEP DIVE SESSION 12 Oral (Podium) Abstract Presentations	
Moderators	Servet Akar (Turkey), Maria Laura Bertolaccini (UK), Doruk Erkan (USA)	Moderators	Ali Akdogan (Turkey), Anisur Rahman (UK)
Room	Hall A	Room	Hall B
3.45 pm	Antiphospholipid Antibodies & Brain: Neuroimaging Findings Simone Appenzeller (Brazil)	3.45 pm	OP19 - The First Genome-Wide Association Study Identifying TSHR as A New Susceptibility Locus for Obstetric APS Mayumi Sugiura-Ogasawara (Japan), Yosuke Omae, Minae Kawashima, Licht Toyo-oka, Seik-Soon Khor, Hiromi Sawai, Tetsuya Horita, Tatsuya Atsumi, Atsuko Murashima, Tamao Kitaori, Kinue Katano, Yasuhiko Ozaki, Katsushi Tokunaga
4.05 pm	Antiphospholipid Antibodies & Brain: Non-vascular Manifestations & Treatment Options Giovanni Sanna (UK)	4.00 pm	PP044 (Late-breaking Abstract) - PEGylated DI Inhibits Thrombosis in a Mouse Model of APS Thomas Christopher Richard McDonnell, Rohan Willis, Charis Pericleous, Zurina Romay-Penabad, Ian Giles, Yiannis Ioannou, Elizabeth Papalardo, <u>Anisur Rahman (UK)</u>
4.25 pm	Antiphospholipid Antibodies & Cognitive Dysfunction: Clinical Perspectives Elizabeth Kozora (USA)	4.15 pm	OP20 - Early Endosome as a Potential Target for Phosphatidylethanolamine-Binding Agents Songwang Hou, Heike Folsch, Steven E Johnson, Ke Ke, <u>Ming Zhao (USA)</u>
4.45 pm	Antiphospholipid Antibodies & Cognitive Dysfunction: Potential Mechanisms and the Effect of aPL in Mouse Fetal Brain Development Guillermina Girardi (UK)	4.30 pm	OP21 - The Clinical Relevance of Antibodies Against Domain 1 and Domain 4/5 of β_2 Glycoprotein I in Obstetric APS <u>Cecilia Beatrice Chighizola (Italy)</u> , Laura Andreoli, Marta Tonello, Maria Gabriella Raimondo, Francesca Pregnolato, Cecilia Nalli, Elena Mattia, Laura Cesana, Rajesh Kumar, Chiara Comerio, Claudia Grossi, Francesco Mombelli, Maria Gerosa, Maria Orietta Borghi, Amelia Ruffatti, Angela Tincani, Pier Luigi Meroni
5.05 pm	Group Conclusions	4.45 pm	OP22 – Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein I are Strongly Associated with The Occurrence of Acute Thrombotic Events <u>Jose Angel Martinez-Flores (Spain)</u> , Oscar Cabrera, Manuel Serrano, Dolopres Perez, Margarita Sevilla Sergio Mora, Rosa Ayala, Luis Morillas, Jose Maria Morales, Antonio Serrano
		5.00 pm	OP23 - Circulating Endothelial Cells Can Identify Patients with Antiphospholipid-Antibodies at Risk for Thrombosis <u>Stéphane Zuily (France)</u> , Marie Heymonet, Tu Qian, Marcelo De Carvalho, Gilbert Faure, Denis Wahl
5.15 5.30	Congress Closing Remarks	5.15 5.30	Congress Closing Remarks